List of news related to Elevance Health stock price ELV:

Title: Ensign Peak Advisors Inc Acquires 2,862 Shares of Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/23/ensign-peak-advisors-inc-acquires-2862-shares-of-elevance-health-inc-nyseelv/
Time Published: 2024-09-23T12:47:56Z
Full Content:
Posted by MarketBeat News on Sep 23rd, 2024 Ensign Peak Advisors Inc boosted its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 5.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 60,115 shares of the company’s stock after purchasing an additional 2,862 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Elevance Health were worth $32,574,000 at the end of the most recent quarter. Several other institutional investors have also recently added to or reduced their stakes in the business. Bank & Trust Co bought a new stake in Elevance Health in the 2nd quarter valued at about $27,000. Pin Oak Investment Advisors Inc. acquired a new stake in Elevance Health in the fourth quarter valued at approximately $28,000. Palisade Asset Management LLC bought a new stake in shares of Elevance Health during the first quarter valued at approximately $28,000. Opal Wealth Advisors LLC acquired a new position in shares of Elevance Health during the second quarter worth approximately $28,000. Finally, Strategic Financial Concepts LLC bought a new position in shares of Elevance Health in the 2nd quarter worth $30,000. 89.24% of the stock is owned by institutional investors and hedge funds. Several research firms have weighed in on ELV. Stephens restated an “overweight” rating and set a $615.00 price objective on shares of Elevance Health in a report on Thursday, September 5th. Robert W. Baird initiated coverage on shares of Elevance Health in a research report on Thursday, May 30th. They issued an “outperform” rating and a $649.00 price target on the stock. Truist Financial lifted their price target on Elevance Health from $600.00 to $620.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Royal Bank of Canada increased their price objective on Elevance Health from $575.00 to $585.00 and gave the stock an “outperform” rating in a research note on Thursday, July 18th. Finally, Bank of America reaffirmed a “neutral” rating and set a $530.00 target price (down previously from $646.00) on shares of Elevance Health in a research report on Thursday, July 18th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $604.29. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Check Out Our Latest Research Report on ELV In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the sale, the director now directly owns 8,744 shares of the company’s stock, valued at $4,647,610.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $531.52, for a total transaction of $400,234.56. Following the sale, the director now owns 8,744 shares in the company, valued at $4,647,610.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert L. Dixon, Jr. sold 305 shares of the firm’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the transaction, the director now directly owns 9,721 shares of the company’s stock, valued at $4,926,213.96. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,058 shares of company stock worth $17,588,116. 0.35% of the stock is owned by company insiders. Shares of NYSE:ELV opened at $539.86 on Monday. The company has a market capitalization of $125.47 billion, a P/E ratio of 20.40, a price-to-earnings-growth ratio of 1.19 and a beta of 0.82. The company’s 50-day moving average is $536.19 and its 200 day moving average is $529.47. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.49 and a current ratio of 1.49. Elevance Health, Inc. has a fifty-two week low of $431.38 and a fifty-two week high of $567.26. Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.99 by $0.13. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The company had revenue of $43.22 billion during the quarter, compared to analyst estimates of $42.99 billion. During the same quarter last year, the business posted $9.04 EPS. Elevance Health’s quarterly revenue was down .4% compared to the same quarter last year. On average, equities research analysts forecast that Elevance Health, Inc. will post 37.25 earnings per share for the current year. The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be paid a dividend of $1.63 per share. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.21%. Elevance Health’s payout ratio is 24.64%. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Ensign Peak Advisors Inc Boosts Stake in Lululemon Athletica Inc. (NASDAQ:LULU) Ensign Peak Advisors Inc Boosts Position in FTAI Aviation Ltd. (NYSE:FTAI)
--------------------------------------------------

Title: 1832 Asset Management L.P. Has $333.64 Million Holdings in Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/22/1832-asset-management-l-p-has-333-64-million-holdings-in-elevance-health-inc-nyseelv/
Time Published: 2024-09-22T19:40:14Z
Full Content:
Posted by MarketBeat News on Sep 22nd, 2024 1832 Asset Management L.P. cut its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 0.9% during the 2nd quarter, HoldingsChannel reports. The fund owned 615,738 shares of the company’s stock after selling 5,622 shares during the quarter. 1832 Asset Management L.P.’s holdings in Elevance Health were worth $333,644,000 as of its most recent filing with the SEC. Other institutional investors and hedge funds have also modified their holdings of the company. Tower Research Capital LLC TRC lifted its position in Elevance Health by 114.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 31,311 shares of the company’s stock worth $14,765,000 after purchasing an additional 16,737 shares during the period. Brave Warrior Advisors LLC lifted its position in Elevance Health by 7.9% during the fourth quarter. Brave Warrior Advisors LLC now owns 1,756,653 shares of the company’s stock worth $828,367,000 after purchasing an additional 129,055 shares during the period. New Mexico Educational Retirement Board lifted its position in Elevance Health by 14.6% during the first quarter. New Mexico Educational Retirement Board now owns 14,146 shares of the company’s stock worth $6,949,000 after purchasing an additional 1,800 shares during the period. Bank of Nova Scotia lifted its position in Elevance Health by 276.0% during the fourth quarter. Bank of Nova Scotia now owns 82,331 shares of the company’s stock worth $38,823,000 after purchasing an additional 60,436 shares during the period. Finally, Blair William & Co. IL lifted its position in Elevance Health by 119.7% during the first quarter. Blair William & Co. IL now owns 12,134 shares of the company’s stock worth $6,292,000 after purchasing an additional 6,610 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds. Several equities research analysts recently weighed in on ELV shares. JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $628.00 to $631.00 and gave the stock an “overweight” rating in a research report on Thursday, May 30th. Baird R W raised shares of Elevance Health to a “strong-buy” rating in a report on Thursday, May 30th. Stephens reissued an “overweight” rating and issued a $615.00 target price on shares of Elevance Health in a report on Thursday, September 5th. StockNews.com cut shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 6th. Finally, Truist Financial increased their target price on shares of Elevance Health from $600.00 to $620.00 and gave the stock a “buy” rating in a report on Monday, July 15th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $604.29. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Get Our Latest Report on ELV Elevance Health stock opened at $539.86 on Friday. The business has a 50 day moving average of $536.19 and a 200-day moving average of $529.30. Elevance Health, Inc. has a 1 year low of $431.38 and a 1 year high of $567.26. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.49. The company has a market capitalization of $125.47 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.19 and a beta of 0.82. Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.99 by $0.13. Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. The company had revenue of $43.22 billion during the quarter, compared to the consensus estimate of $42.99 billion. During the same quarter in the prior year, the firm posted $9.04 earnings per share. The firm’s revenue was down .4% compared to the same quarter last year. On average, equities research analysts predict that Elevance Health, Inc. will post 37.25 earnings per share for the current year. The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th will be given a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date of this dividend is Tuesday, September 10th. Elevance Health’s dividend payout ratio is presently 24.64%. In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the sale, the director now owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction that occurred on Friday, July 19th. The shares were sold at an average price of $506.76, for a total transaction of $154,561.80. Following the completion of the sale, the director now owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ramiro G. Peru sold 753 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the sale, the director now directly owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,058 shares of company stock valued at $17,588,116. 0.35% of the stock is currently owned by company insiders. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. The Home Depot, Inc. (NYSE:HD) Stake Raised by 1832 Asset Management L.P. Canadian Pacific Kansas City Limited (NYSE:CP) Shares Acquired by 1832 Asset Management L.P.
--------------------------------------------------

Title: Fidelis Capital Partners LLC Acquires 1,168 Shares of Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/22/fidelis-capital-partners-llc-acquires-1168-shares-of-elevance-health-inc-nyseelv/
Time Published: 2024-09-22T18:32:54Z
Full Content:
Posted by MarketBeat News on Sep 22nd, 2024 Fidelis Capital Partners LLC increased its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 49.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,552 shares of the company’s stock after buying an additional 1,168 shares during the period. Fidelis Capital Partners LLC’s holdings in Elevance Health were worth $1,851,000 as of its most recent SEC filing. Other hedge funds have also bought and sold shares of the company. Massachusetts Financial Services Co. MA grew its position in shares of Elevance Health by 34.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,062,706 shares of the company’s stock valued at $1,117,698,000 after purchasing an additional 523,910 shares in the last quarter. Morningstar Investment Services LLC bought a new position in shares of Elevance Health in the fourth quarter valued at approximately $239,244,000. Focused Investors Fund L P purchased a new position in Elevance Health during the first quarter valued at approximately $249,884,000. M&G Plc bought a new stake in Elevance Health during the 1st quarter worth approximately $203,389,000. Finally, Maj Invest Holding A S purchased a new stake in Elevance Health in the 2nd quarter worth approximately $173,753,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors. Elevance Health stock opened at $539.86 on Friday. The firm has a fifty day simple moving average of $536.19 and a two-hundred day simple moving average of $529.30. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health, Inc. has a twelve month low of $431.38 and a twelve month high of $567.26. The company has a market capitalization of $125.47 billion, a PE ratio of 20.40, a P/E/G ratio of 1.19 and a beta of 0.82. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share for the quarter, beating analysts’ consensus estimates of $9.99 by $0.13. Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. The company had revenue of $43.22 billion during the quarter, compared to analyst estimates of $42.99 billion. During the same quarter in the previous year, the company posted $9.04 EPS. Elevance Health’s revenue for the quarter was down .4% on a year-over-year basis. Research analysts expect that Elevance Health, Inc. will post 37.25 EPS for the current year. The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be paid a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Tuesday, September 10th. Elevance Health’s dividend payout ratio (DPR) is presently 24.64%. Several research firms have recently weighed in on ELV. Royal Bank of Canada upped their price target on shares of Elevance Health from $575.00 to $585.00 and gave the stock an “outperform” rating in a report on Thursday, July 18th. TD Cowen lowered their price target on Elevance Health from $624.00 to $589.00 and set a “buy” rating on the stock in a report on Friday, July 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $600.00 price objective on shares of Elevance Health in a report on Friday. Robert W. Baird started coverage on shares of Elevance Health in a research note on Thursday, May 30th. They issued an “outperform” rating and a $649.00 target price on the stock. Finally, Bank of America reissued a “neutral” rating and issued a $530.00 price target (down previously from $646.00) on shares of Elevance Health in a research note on Thursday, July 18th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $604.29. Read Our Latest Stock Analysis on Elevance Health In other Elevance Health news, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the completion of the sale, the chief executive officer now owns 126,709 shares of the company’s stock, valued at approximately $63,478,674.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Gail Boudreaux sold 34,000 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the completion of the transaction, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at $63,478,674.82. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the sale, the director now owns 9,721 shares of the company’s stock, valued at $4,926,213.96. The disclosure for this sale can be found here. Insiders have sold a total of 35,058 shares of company stock valued at $17,588,116 over the last three months. 0.35% of the stock is owned by company insiders. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Epoch Investment Partners Inc. Sells 30,123 Shares of Verizon Communications Inc. (NYSE:VZ) Danaher Co. (NYSE:DHR) Shares Sold by Fidelis Capital Partners LLC
--------------------------------------------------

Title: Hancock Whitney Corp Reduces Stock Holdings in Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/22/hancock-whitney-corp-reduces-stock-holdings-in-elevance-health-inc-nyseelv/
Time Published: 2024-09-22T17:49:03Z
Full Content:
Posted by MarketBeat News on Sep 22nd, 2024 Hancock Whitney Corp lowered its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 3.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,449 shares of the company’s stock after selling 127 shares during the period. Hancock Whitney Corp’s holdings in Elevance Health were worth $1,869,000 at the end of the most recent reporting period. A number of other hedge funds have also added to or reduced their stakes in ELV. Bell Investment Advisors Inc increased its position in shares of Elevance Health by 2.1% during the fourth quarter. Bell Investment Advisors Inc now owns 989 shares of the company’s stock valued at $466,000 after buying an additional 20 shares during the period. Capital Advisors Ltd. LLC raised its position in shares of Elevance Health by 8.8% in the 1st quarter. Capital Advisors Ltd. LLC now owns 248 shares of the company’s stock worth $129,000 after acquiring an additional 20 shares in the last quarter. Bedel Financial Consulting Inc. lifted its stake in shares of Elevance Health by 1.6% in the 1st quarter. Bedel Financial Consulting Inc. now owns 1,247 shares of the company’s stock valued at $647,000 after purchasing an additional 20 shares during the period. American Trust boosted its position in shares of Elevance Health by 2.6% during the first quarter. American Trust now owns 775 shares of the company’s stock valued at $402,000 after purchasing an additional 20 shares in the last quarter. Finally, Sage Rhino Capital LLC grew its stake in Elevance Health by 4.6% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the company’s stock worth $246,000 after purchasing an additional 21 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors. In other news, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction that occurred on Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the transaction, the director now owns 9,721 shares in the company, valued at approximately $4,926,213.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Robert L. Dixon, Jr. sold 305 shares of the firm’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the transaction, the director now directly owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ramiro G. Peru sold 753 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total value of $400,234.56. Following the sale, the director now directly owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. The disclosure for this sale can be found here. Insiders sold a total of 35,058 shares of company stock worth $17,588,116 in the last three months. 0.35% of the stock is currently owned by company insiders. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever A number of brokerages have recently commented on ELV. JPMorgan Chase & Co. boosted their target price on shares of Elevance Health from $628.00 to $631.00 and gave the company an “overweight” rating in a report on Thursday, May 30th. Stephens restated an “overweight” rating and issued a $615.00 price objective on shares of Elevance Health in a report on Thursday, September 5th. Bank of America reiterated a “neutral” rating and set a $530.00 target price (down from $646.00) on shares of Elevance Health in a report on Thursday, July 18th. Baird R W upgraded Elevance Health to a “strong-buy” rating in a research note on Thursday, May 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $600.00 price objective on shares of Elevance Health in a research note on Friday. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $604.29. Check Out Our Latest Stock Analysis on Elevance Health Shares of NYSE:ELV opened at $539.86 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.49 and a current ratio of 1.49. The firm has a market cap of $125.47 billion, a price-to-earnings ratio of 20.40, a price-to-earnings-growth ratio of 1.19 and a beta of 0.82. The business has a 50-day simple moving average of $536.19 and a two-hundred day simple moving average of $529.30. Elevance Health, Inc. has a fifty-two week low of $431.38 and a fifty-two week high of $567.26. Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share for the quarter, beating analysts’ consensus estimates of $9.99 by $0.13. The company had revenue of $43.22 billion for the quarter, compared to the consensus estimate of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $9.04 earnings per share. On average, analysts expect that Elevance Health, Inc. will post 37.25 earnings per share for the current year. The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th will be given a $1.63 dividend. The ex-dividend date of this dividend is Tuesday, September 10th. This represents a $6.52 annualized dividend and a yield of 1.21%. Elevance Health’s payout ratio is 24.64%. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Vanguard Mid-Cap ETF (NYSEARCA:VO) is Fischer Investment Strategies LLC’s 3rd Largest Position Hancock Whitney Corp Acquires 565 Shares of Canadian Pacific Kansas City Limited (NYSE:CP)
--------------------------------------------------

Title: Sound Shore Management Inc. CT Sells 32,574 Shares of Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/21/sound-shore-management-inc-ct-sells-32574-shares-of-elevance-health-inc-nyseelv/
Time Published: 2024-09-21T20:41:12Z
Full Content:
Posted by MarketBeat News on Sep 21st, 2024 Sound Shore Management Inc. CT reduced its stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 21.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 122,069 shares of the company’s stock after selling 32,574 shares during the period. Sound Shore Management Inc. CT’s holdings in Elevance Health were worth $66,144,000 at the end of the most recent quarter. Other large investors have also recently made changes to their positions in the company. Bank & Trust Co acquired a new position in Elevance Health during the 2nd quarter valued at about $27,000. Pin Oak Investment Advisors Inc. purchased a new stake in Elevance Health during the fourth quarter worth $28,000. Palisade Asset Management LLC purchased a new position in Elevance Health during the first quarter worth approximately $28,000. Opal Wealth Advisors LLC acquired a new stake in Elevance Health in the 2nd quarter worth about $28,000. Finally, Strategic Financial Concepts LLC purchased a new stake in shares of Elevance Health during the second quarter worth approximately $30,000. 89.24% of the stock is owned by hedge funds and other institutional investors. Several research firms have recently commented on ELV. JPMorgan Chase & Co. lifted their price target on Elevance Health from $628.00 to $631.00 and gave the stock an “overweight” rating in a report on Thursday, May 30th. Bank of America restated a “neutral” rating and issued a $530.00 price objective (down previously from $646.00) on shares of Elevance Health in a report on Thursday, July 18th. Baird R W upgraded shares of Elevance Health to a “strong-buy” rating in a research note on Thursday, May 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $600.00 price target on shares of Elevance Health in a report on Friday. Finally, Royal Bank of Canada lifted their price target on shares of Elevance Health from $575.00 to $585.00 and gave the stock an “outperform” rating in a research note on Thursday, July 18th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $604.29. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Get Our Latest Research Report on ELV ELV stock opened at $539.79 on Friday. The company has a fifty day simple moving average of $536.19 and a 200 day simple moving average of $529.08. Elevance Health, Inc. has a 1 year low of $431.38 and a 1 year high of $567.26. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. The firm has a market cap of $125.46 billion, a PE ratio of 20.40, a PEG ratio of 1.19 and a beta of 0.82. Elevance Health (NYSE:ELV – Get Free Report) last issued its earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share for the quarter, beating the consensus estimate of $9.99 by $0.13. The business had revenue of $43.22 billion for the quarter, compared to analyst estimates of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The firm’s revenue was down .4% on a year-over-year basis. During the same period in the previous year, the business earned $9.04 EPS. Sell-side analysts anticipate that Elevance Health, Inc. will post 37.25 EPS for the current fiscal year. The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th will be given a $1.63 dividend. The ex-dividend date of this dividend is Tuesday, September 10th. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.21%. Elevance Health’s dividend payout ratio is 24.64%. In related news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $531.52, for a total value of $400,234.56. Following the sale, the director now owns 8,744 shares of the company’s stock, valued at $4,647,610.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Gail Boudreaux sold 34,000 shares of Elevance Health stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total value of $17,033,320.00. Following the transaction, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at $63,478,674.82. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the sale, the director now directly owns 8,744 shares in the company, valued at approximately $4,647,610.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,058 shares of company stock worth $17,588,116. Corporate insiders own 0.35% of the company’s stock. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Ensign Peak Advisors Inc Trims Stake in Oracle Co. (NYSE:ORCL) Verizon Communications Inc. (NYSE:VZ) Stake Lessened by Sompo Asset Management Co. Ltd.
--------------------------------------------------

Title: Sompo Asset Management Co. Ltd. Has $921,000 Stock Holdings in Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/21/sompo-asset-management-co-ltd-has-921000-stock-holdings-in-elevance-health-inc-nyseelv/
Time Published: 2024-09-21T18:40:58Z
Full Content:
Posted by MarketBeat News on Sep 21st, 2024 Sompo Asset Management Co. Ltd. lessened its stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 6.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,700 shares of the company’s stock after selling 120 shares during the period. Sompo Asset Management Co. Ltd.’s holdings in Elevance Health were worth $921,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Accretive Wealth Partners LLC acquired a new stake in shares of Elevance Health in the fourth quarter worth $209,000. D.A. Davidson & CO. grew its stake in shares of Elevance Health by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 5,657 shares of the company’s stock worth $2,668,000 after acquiring an additional 69 shares during the last quarter. CreativeOne Wealth LLC grew its stake in shares of Elevance Health by 56.9% in the fourth quarter. CreativeOne Wealth LLC now owns 786 shares of the company’s stock worth $371,000 after acquiring an additional 285 shares during the last quarter. King Luther Capital Management Corp acquired a new stake in shares of Elevance Health in the fourth quarter worth $316,000. Finally, US Bancorp DE grew its stake in shares of Elevance Health by 4.1% in the fourth quarter. US Bancorp DE now owns 60,461 shares of the company’s stock worth $28,512,000 after acquiring an additional 2,396 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock. In other news, CEO Gail Boudreaux sold 34,000 shares of the firm’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $500.98, for a total value of $17,033,320.00. Following the transaction, the chief executive officer now owns 126,709 shares of the company’s stock, valued at approximately $63,478,674.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Gail Boudreaux sold 34,000 shares of the firm’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $500.98, for a total value of $17,033,320.00. Following the transaction, the chief executive officer now owns 126,709 shares of the company’s stock, valued at approximately $63,478,674.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ramiro G. Peru sold 753 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the transaction, the director now directly owns 8,744 shares in the company, valued at approximately $4,647,610.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,058 shares of company stock valued at $17,588,116. 0.35% of the stock is currently owned by insiders. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Several brokerages have recently issued reports on ELV. Royal Bank of Canada raised their price objective on shares of Elevance Health from $575.00 to $585.00 and gave the stock an “outperform” rating in a research note on Thursday, July 18th. Stephens reaffirmed an “overweight” rating and issued a $615.00 target price on shares of Elevance Health in a research report on Thursday, September 5th. JPMorgan Chase & Co. raised their target price on Elevance Health from $628.00 to $631.00 and gave the stock an “overweight” rating in a research report on Thursday, May 30th. TD Cowen reduced their target price on Elevance Health from $624.00 to $589.00 and set a “buy” rating for the company in a research report on Friday, July 19th. Finally, Truist Financial raised their target price on Elevance Health from $600.00 to $620.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $604.29. Get Our Latest Stock Report on ELV Elevance Health stock opened at $539.79 on Friday. The stock has a 50-day simple moving average of $536.19 and a 200 day simple moving average of $529.08. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health, Inc. has a 12-month low of $431.38 and a 12-month high of $567.26. The stock has a market capitalization of $125.46 billion, a price-to-earnings ratio of 20.40, a P/E/G ratio of 1.19 and a beta of 0.82. Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.99 by $0.13. The company had revenue of $43.22 billion for the quarter, compared to the consensus estimate of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The company’s revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company posted $9.04 EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 37.25 earnings per share for the current fiscal year. The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be paid a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.21%. The ex-dividend date is Tuesday, September 10th. Elevance Health’s dividend payout ratio (DPR) is presently 24.64%. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Asset Management Group Inc. Trims Position in iShares S&P Small-Cap 600 Growth ETF (NASDAQ:IJT) Pimco Total Return ETF (NYSEARCA:BOND) Shares Bought by Asset Management Group Inc.
--------------------------------------------------

Title: Arista Wealth Management LLC Takes Position in Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/21/arista-wealth-management-llc-takes-position-in-elevance-health-inc-nyseelv/
Time Published: 2024-09-21T18:07:11Z
Full Content:
Posted by MarketBeat News on Sep 21st, 2024 Arista Wealth Management LLC acquired a new stake in Elevance Health, Inc. (NYSE:ELV – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 858 shares of the company’s stock, valued at approximately $465,000. Several other institutional investors have also added to or reduced their stakes in ELV. Sei Investments Co. increased its holdings in Elevance Health by 10.2% in the 2nd quarter. Sei Investments Co. now owns 123,872 shares of the company’s stock worth $67,117,000 after buying an additional 11,513 shares in the last quarter. AE Wealth Management LLC grew its holdings in shares of Elevance Health by 13.9% in the second quarter. AE Wealth Management LLC now owns 5,205 shares of the company’s stock worth $2,820,000 after acquiring an additional 637 shares during the period. Callan Capital LLC increased its position in Elevance Health by 83.4% during the second quarter. Callan Capital LLC now owns 860 shares of the company’s stock valued at $466,000 after acquiring an additional 391 shares during the last quarter. Benjamin Edwards Inc. boosted its position in Elevance Health by 1.4% in the second quarter. Benjamin Edwards Inc. now owns 2,956 shares of the company’s stock worth $1,602,000 after purchasing an additional 41 shares during the last quarter. Finally, Trust Investment Advisors grew its stake in shares of Elevance Health by 12.6% during the 2nd quarter. Trust Investment Advisors now owns 509 shares of the company’s stock valued at $276,000 after purchasing an additional 57 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors. NYSE ELV opened at $539.79 on Friday. The stock has a 50 day moving average price of $536.19 and a 200-day moving average price of $529.08. Elevance Health, Inc. has a one year low of $431.38 and a one year high of $567.26. The company has a market capitalization of $125.46 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.19 and a beta of 0.82. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.49 and a current ratio of 1.49. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Elevance Health (NYSE:ELV – Get Free Report) last announced its earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.99 by $0.13. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The firm had revenue of $43.22 billion for the quarter, compared to analysts’ expectations of $42.99 billion. During the same period in the prior year, the company earned $9.04 EPS. The business’s revenue was down .4% compared to the same quarter last year. As a group, equities analysts predict that Elevance Health, Inc. will post 37.25 EPS for the current fiscal year. The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th will be given a $1.63 dividend. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.21%. Elevance Health’s dividend payout ratio is presently 24.64%. In other news, Director Robert L. Dixon, Jr. sold 305 shares of the firm’s stock in a transaction dated Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the sale, the director now owns 9,721 shares in the company, valued at approximately $4,926,213.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Robert L. Dixon, Jr. sold 305 shares of the business’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the completion of the transaction, the director now owns 9,721 shares in the company, valued at approximately $4,926,213.96. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total value of $17,033,320.00. Following the completion of the transaction, the chief executive officer now directly owns 126,709 shares in the company, valued at approximately $63,478,674.82. The disclosure for this sale can be found here. Insiders sold 35,058 shares of company stock valued at $17,588,116 over the last three months. 0.35% of the stock is owned by company insiders. Several analysts recently issued reports on ELV shares. JPMorgan Chase & Co. boosted their target price on shares of Elevance Health from $628.00 to $631.00 and gave the company an “overweight” rating in a research report on Thursday, May 30th. Truist Financial raised their target price on Elevance Health from $600.00 to $620.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Baird R W upgraded Elevance Health to a “strong-buy” rating in a research report on Thursday, May 30th. Stephens reiterated an “overweight” rating and set a $615.00 price objective on shares of Elevance Health in a research note on Thursday, September 5th. Finally, Morgan Stanley assumed coverage on shares of Elevance Health in a research report on Monday, June 24th. They issued an “overweight” rating and a $643.00 price target for the company. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $604.29. Get Our Latest Research Report on ELV (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Lodge Hill Capital LLC Has $17.90 Million Position in NOV Inc. (NYSE:NOV) Bulltick Wealth Management LLC Has $3.51 Million Stock Position in iShares 1-3 Year Treasury Bond ETF (NASDAQ:SHY)
--------------------------------------------------

Title: 2,900 Shares in Elevance Health, Inc. (NYSE:ELV) Acquired by Symmetry Investments LP
URL: https://www.etfdailynews.com/2024/09/21/2900-shares-in-elevance-health-inc-nyseelv-acquired-by-symmetry-investments-lp/
Time Published: 2024-09-21T13:27:21Z
Full Content:
Posted by MarketBeat News on Sep 21st, 2024 Symmetry Investments LP purchased a new position in Elevance Health, Inc. (NYSE:ELV – Free Report) during the second quarter, HoldingsChannel reports. The firm purchased 2,900 shares of the company’s stock, valued at approximately $1,571,000. Other large investors also recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its holdings in shares of Elevance Health by 114.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 31,311 shares of the company’s stock worth $14,765,000 after buying an additional 16,737 shares during the last quarter. Brave Warrior Advisors LLC grew its position in shares of Elevance Health by 7.9% during the 4th quarter. Brave Warrior Advisors LLC now owns 1,756,653 shares of the company’s stock valued at $828,367,000 after acquiring an additional 129,055 shares during the period. New Mexico Educational Retirement Board increased its stake in shares of Elevance Health by 14.6% in the 1st quarter. New Mexico Educational Retirement Board now owns 14,146 shares of the company’s stock worth $6,949,000 after purchasing an additional 1,800 shares in the last quarter. Bank of Nova Scotia raised its holdings in Elevance Health by 276.0% in the 4th quarter. Bank of Nova Scotia now owns 82,331 shares of the company’s stock worth $38,823,000 after purchasing an additional 60,436 shares during the period. Finally, Blair William & Co. IL increased its position in Elevance Health by 119.7% in the first quarter. Blair William & Co. IL now owns 12,134 shares of the company’s stock worth $6,292,000 after buying an additional 6,610 shares in the last quarter. Institutional investors own 89.24% of the company’s stock. In other news, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the transaction, the director now owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Robert L. Dixon, Jr. sold 305 shares of the company’s stock in a transaction that occurred on Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the sale, the director now owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $531.52, for a total value of $400,234.56. Following the sale, the director now owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,058 shares of company stock valued at $17,588,116. Corporate insiders own 0.35% of the company’s stock. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Shares of Elevance Health stock opened at $539.79 on Friday. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health, Inc. has a 12 month low of $431.38 and a 12 month high of $567.26. The stock has a 50 day moving average of $536.19 and a 200 day moving average of $529.08. The firm has a market cap of $125.46 billion, a PE ratio of 20.40, a PEG ratio of 1.19 and a beta of 0.82. Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.99 by $0.13. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The company had revenue of $43.22 billion for the quarter, compared to the consensus estimate of $42.99 billion. During the same quarter in the prior year, the firm earned $9.04 earnings per share. Elevance Health’s revenue was down .4% on a year-over-year basis. On average, research analysts expect that Elevance Health, Inc. will post 37.25 EPS for the current fiscal year. The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th will be paid a $1.63 dividend. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.21%. Elevance Health’s dividend payout ratio is currently 24.64%. A number of research analysts recently issued reports on the company. Baird R W upgraded Elevance Health to a “strong-buy” rating in a research note on Thursday, May 30th. JPMorgan Chase & Co. increased their price objective on shares of Elevance Health from $628.00 to $631.00 and gave the stock an “overweight” rating in a research note on Thursday, May 30th. Barclays decreased their price objective on shares of Elevance Health from $621.00 to $611.00 and set an “overweight” rating on the stock in a research report on Thursday, July 18th. Morgan Stanley started coverage on Elevance Health in a research note on Monday, June 24th. They issued an “overweight” rating and a $643.00 price target for the company. Finally, Wells Fargo & Company decreased their price target on Elevance Health from $600.00 to $593.00 and set an “overweight” rating on the stock in a report on Monday, July 22nd. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Elevance Health has an average rating of “Buy” and a consensus price target of $604.29. Check Out Our Latest Research Report on Elevance Health (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by Connecticut Wealth Management LLC Symmetry Investments LP Makes New $1.46 Million Investment in Corebridge Financial, Inc. (NYSE:CRBG)
--------------------------------------------------

Title: Canada Pension Plan Investment Board Sells 117,595 Shares of Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/20/canada-pension-plan-investment-board-sells-117595-shares-of-elevance-health-inc-nyseelv/
Time Published: 2024-09-20T20:40:42Z
Full Content:
Posted by MarketBeat News on Sep 20th, 2024 Canada Pension Plan Investment Board cut its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 20.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 450,770 shares of the company’s stock after selling 117,595 shares during the quarter. Canada Pension Plan Investment Board owned 0.19% of Elevance Health worth $244,254,000 at the end of the most recent quarter. Other institutional investors and hedge funds also recently modified their holdings of the company. Tower Research Capital LLC TRC increased its stake in Elevance Health by 114.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 31,311 shares of the company’s stock valued at $14,765,000 after purchasing an additional 16,737 shares in the last quarter. Brave Warrior Advisors LLC grew its holdings in shares of Elevance Health by 7.9% in the 4th quarter. Brave Warrior Advisors LLC now owns 1,756,653 shares of the company’s stock valued at $828,367,000 after buying an additional 129,055 shares during the period. New Mexico Educational Retirement Board increased its position in shares of Elevance Health by 14.6% in the 1st quarter. New Mexico Educational Retirement Board now owns 14,146 shares of the company’s stock valued at $6,949,000 after buying an additional 1,800 shares in the last quarter. Bank of Nova Scotia increased its position in shares of Elevance Health by 276.0% in the 4th quarter. Bank of Nova Scotia now owns 82,331 shares of the company’s stock valued at $38,823,000 after buying an additional 60,436 shares in the last quarter. Finally, Blair William & Co. IL raised its stake in Elevance Health by 119.7% during the 1st quarter. Blair William & Co. IL now owns 12,134 shares of the company’s stock worth $6,292,000 after buying an additional 6,610 shares during the period. 89.24% of the stock is owned by institutional investors. In other news, Director Robert L. Dixon, Jr. sold 305 shares of Elevance Health stock in a transaction dated Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the transaction, the director now owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Robert L. Dixon, Jr. sold 305 shares of the business’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the transaction, the director now directly owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Gail Boudreaux sold 34,000 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $500.98, for a total value of $17,033,320.00. Following the sale, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at approximately $63,478,674.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,058 shares of company stock valued at $17,588,116. 0.35% of the stock is currently owned by corporate insiders. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever A number of research analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Elevance Health from $628.00 to $631.00 and gave the company an “overweight” rating in a research note on Thursday, May 30th. StockNews.com lowered Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 6th. Baird R W upgraded shares of Elevance Health to a “strong-buy” rating in a report on Thursday, May 30th. TD Cowen cut their price target on shares of Elevance Health from $624.00 to $589.00 and set a “buy” rating on the stock in a research note on Friday, July 19th. Finally, Royal Bank of Canada increased their price objective on shares of Elevance Health from $575.00 to $585.00 and gave the stock an “outperform” rating in a research report on Thursday, July 18th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $604.29. View Our Latest Report on Elevance Health Shares of NYSE:ELV opened at $538.00 on Friday. The company’s 50-day moving average price is $536.11 and its two-hundred day moving average price is $528.84. Elevance Health, Inc. has a one year low of $431.38 and a one year high of $567.26. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.49. The stock has a market capitalization of $125.04 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.19 and a beta of 0.82. Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.99 by $0.13. The business had revenue of $43.22 billion for the quarter, compared to analyst estimates of $42.99 billion. Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. Elevance Health’s revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the company posted $9.04 earnings per share. On average, equities analysts forecast that Elevance Health, Inc. will post 37.25 EPS for the current fiscal year. The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th will be issued a dividend of $1.63 per share. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.21%. Elevance Health’s payout ratio is 24.64%. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. iShares iBonds Dec 2025 Term Corporate ETF (NYSEARCA:IBDQ) Sees Strong Trading Volume Canada Pension Plan Investment Board Has $500.26 Million Position in ServiceNow, Inc. (NYSE:NOW)
--------------------------------------------------

Title: Elevance Health (NYSE:ELV) Rating Reiterated by Cantor Fitzgerald
URL: https://www.etfdailynews.com/2024/09/20/elevance-health-nyseelv-rating-reiterated-by-cantor-fitzgerald/
Time Published: 2024-09-20T16:20:14Z
Full Content:
Posted by MarketBeat News on Sep 20th, 2024 Elevance Health (NYSE:ELV – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They presently have a $600.00 target price on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 11.79% from the stock’s previous close. ELV has been the subject of a number of other reports. StockNews.com downgraded shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 6th. TD Cowen reduced their price target on shares of Elevance Health from $624.00 to $589.00 and set a “buy” rating on the stock in a research report on Friday, July 19th. JPMorgan Chase & Co. increased their price target on Elevance Health from $628.00 to $631.00 and gave the stock an “overweight” rating in a report on Thursday, May 30th. Robert W. Baird assumed coverage on shares of Elevance Health in a report on Thursday, May 30th. They issued an “outperform” rating and a $649.00 price target for the company. Finally, Baird R W upgraded shares of Elevance Health to a “strong-buy” rating in a report on Thursday, May 30th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $604.29. Get Our Latest Analysis on Elevance Health Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever NYSE:ELV traded down $1.29 on Friday, hitting $536.71. 255,882 shares of the stock were exchanged, compared to its average volume of 1,000,697. The stock has a market capitalization of $124.74 billion, a price-to-earnings ratio of 20.28, a P/E/G ratio of 1.19 and a beta of 0.82. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.49 and a current ratio of 1.49. Elevance Health has a 52 week low of $431.38 and a 52 week high of $567.26. The company’s 50-day moving average price is $536.11 and its 200 day moving average price is $528.84. Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.99 by $0.13. The firm had revenue of $43.22 billion for the quarter, compared to analysts’ expectations of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the firm earned $9.04 earnings per share. On average, equities research analysts forecast that Elevance Health will post 37.25 earnings per share for the current year. In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the sale, the director now directly owns 8,744 shares of the company’s stock, valued at $4,647,610.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Robert L. Dixon, Jr. sold 305 shares of the business’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the transaction, the director now directly owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ramiro G. Peru sold 753 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $531.52, for a total value of $400,234.56. Following the completion of the sale, the director now owns 8,744 shares in the company, valued at approximately $4,647,610.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,058 shares of company stock valued at $17,588,116. 0.35% of the stock is owned by corporate insiders. Large investors have recently modified their holdings of the stock. Sanders Capital LLC grew its stake in Elevance Health by 4.6% in the 4th quarter. Sanders Capital LLC now owns 4,457,986 shares of the company’s stock valued at $2,102,208,000 after buying an additional 196,010 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Elevance Health by 5.3% during the second quarter. Ameriprise Financial Inc. now owns 3,791,793 shares of the company’s stock worth $2,054,641,000 after purchasing an additional 190,118 shares during the period. Capital International Investors lifted its holdings in Elevance Health by 3.7% during the 1st quarter. Capital International Investors now owns 3,498,511 shares of the company’s stock worth $1,814,118,000 after purchasing an additional 123,802 shares during the last quarter. Legal & General Group Plc boosted its stake in Elevance Health by 2.9% in the 2nd quarter. Legal & General Group Plc now owns 2,247,091 shares of the company’s stock valued at $1,217,607,000 after purchasing an additional 64,376 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in Elevance Health by 34.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,062,706 shares of the company’s stock valued at $1,117,698,000 after buying an additional 523,910 shares in the last quarter. 89.24% of the stock is owned by institutional investors. (Get Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. FedEx (NYSE:FDX) Price Target Cut to $350.00 by Analysts at JPMorgan Chase & Co. Corning (NYSE:GLW) Price Target Raised to $55.00
--------------------------------------------------

Title: Skandinaviska Enskilda Banken AB publ Lowers Holdings in Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/20/skandinaviska-enskilda-banken-ab-publ-lowers-holdings-in-elevance-health-inc-nyseelv/
Time Published: 2024-09-20T14:53:42Z
Full Content:
Posted by MarketBeat News on Sep 20th, 2024 Skandinaviska Enskilda Banken AB publ trimmed its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 38.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,898 shares of the company’s stock after selling 65,902 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Elevance Health were worth $56,840,000 as of its most recent SEC filing. A number of other large investors also recently added to or reduced their stakes in the company. Bank & Trust Co acquired a new stake in shares of Elevance Health in the second quarter valued at $27,000. Pin Oak Investment Advisors Inc. purchased a new position in shares of Elevance Health during the fourth quarter worth about $28,000. Palisade Asset Management LLC purchased a new position in shares of Elevance Health during the first quarter worth about $28,000. Opal Wealth Advisors LLC purchased a new position in shares of Elevance Health during the second quarter worth about $28,000. Finally, Strategic Financial Concepts LLC purchased a new position in shares of Elevance Health during the second quarter worth about $30,000. 89.24% of the stock is currently owned by institutional investors and hedge funds. ELV has been the subject of a number of research reports. Bank of America reiterated a “neutral” rating and set a $530.00 price target (down from $646.00) on shares of Elevance Health in a research report on Thursday, July 18th. Morgan Stanley assumed coverage on shares of Elevance Health in a research note on Monday, June 24th. They set an “overweight” rating and a $643.00 price objective for the company. Wells Fargo & Company decreased their price target on shares of Elevance Health from $600.00 to $593.00 and set an “overweight” rating for the company in a research report on Monday, July 22nd. Robert W. Baird started coverage on shares of Elevance Health in a report on Thursday, May 30th. They issued an “outperform” rating and a $649.00 price objective on the stock. Finally, Barclays cut their target price on shares of Elevance Health from $621.00 to $611.00 and set an “overweight” rating on the stock in a research note on Thursday, July 18th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Elevance Health has an average rating of “Buy” and an average target price of $604.29. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Check Out Our Latest Stock Report on Elevance Health In related news, Director Ramiro G. Peru sold 753 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the transaction, the director now owns 8,744 shares in the company, valued at $4,647,610.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total value of $400,234.56. Following the completion of the transaction, the director now owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert L. Dixon, Jr. sold 305 shares of Elevance Health stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the sale, the director now directly owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The disclosure for this sale can be found here. Insiders sold 35,058 shares of company stock worth $17,588,116 over the last quarter. 0.35% of the stock is currently owned by company insiders. Shares of ELV stock opened at $538.00 on Friday. Elevance Health, Inc. has a 12-month low of $431.38 and a 12-month high of $567.26. The company has a market capitalization of $125.04 billion, a P/E ratio of 20.33, a P/E/G ratio of 1.19 and a beta of 0.82. The firm has a 50-day moving average price of $536.11 and a 200 day moving average price of $528.84. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share for the quarter, beating the consensus estimate of $9.99 by $0.13. The firm had revenue of $43.22 billion during the quarter, compared to analysts’ expectations of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter last year, the company posted $9.04 EPS. Research analysts forecast that Elevance Health, Inc. will post 37.25 earnings per share for the current fiscal year. The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be issued a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.21%. The ex-dividend date is Tuesday, September 10th. Elevance Health’s dividend payout ratio (DPR) is presently 24.64%. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. iQIYI (NASDAQ:IQ) Shares Gap Up to $2.14 Dana (NYSE:DAN) Shares Gap Down to $10.47
--------------------------------------------------

Title: Bradley Foster & Sargent Inc. CT Sells 25 Shares of Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/20/bradley-foster-sargent-inc-ct-sells-25-shares-of-elevance-health-inc-nyseelv/
Time Published: 2024-09-20T13:51:19Z
Full Content:
Posted by MarketBeat News on Sep 20th, 2024 Bradley Foster & Sargent Inc. CT cut its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 4.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 607 shares of the company’s stock after selling 25 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Elevance Health were worth $329,000 at the end of the most recent reporting period. Several other hedge funds have also recently bought and sold shares of the business. Bank & Trust Co bought a new stake in shares of Elevance Health during the 2nd quarter worth about $27,000. Opal Wealth Advisors LLC acquired a new position in Elevance Health during the second quarter valued at approximately $28,000. Palisade Asset Management LLC bought a new position in shares of Elevance Health in the first quarter valued at approximately $28,000. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Elevance Health in the fourth quarter worth $28,000. Finally, Register Financial Advisors LLC bought a new stake in shares of Elevance Health during the 1st quarter worth $32,000. 89.24% of the stock is owned by institutional investors and hedge funds. NYSE:ELV opened at $538.00 on Friday. The company has a market capitalization of $125.04 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 1.19 and a beta of 0.82. The company has a 50-day moving average of $536.11 and a 200-day moving average of $528.84. Elevance Health, Inc. has a 52 week low of $431.38 and a 52 week high of $567.26. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.49 and a current ratio of 1.49. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share for the quarter, beating analysts’ consensus estimates of $9.99 by $0.13. Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. The company had revenue of $43.22 billion for the quarter, compared to the consensus estimate of $42.99 billion. During the same period in the previous year, the business earned $9.04 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. As a group, equities research analysts anticipate that Elevance Health, Inc. will post 37.25 earnings per share for the current fiscal year. The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th will be paid a dividend of $1.63 per share. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 annualized dividend and a yield of 1.21%. Elevance Health’s dividend payout ratio is currently 24.64%. Several research analysts recently commented on ELV shares. Truist Financial lifted their target price on shares of Elevance Health from $600.00 to $620.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Royal Bank of Canada boosted their price objective on Elevance Health from $575.00 to $585.00 and gave the stock an “outperform” rating in a research report on Thursday, July 18th. Baird R W raised Elevance Health to a “strong-buy” rating in a report on Thursday, May 30th. Morgan Stanley began coverage on Elevance Health in a report on Monday, June 24th. They set an “overweight” rating and a $643.00 price target for the company. Finally, Bank of America restated a “neutral” rating and issued a $530.00 price objective (down previously from $646.00) on shares of Elevance Health in a research note on Thursday, July 18th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $604.29. Check Out Our Latest Research Report on ELV In related news, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the completion of the sale, the chief executive officer now owns 126,709 shares in the company, valued at approximately $63,478,674.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the sale, the chief executive officer now directly owns 126,709 shares in the company, valued at approximately $63,478,674.82. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert L. Dixon, Jr. sold 305 shares of Elevance Health stock in a transaction dated Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the transaction, the director now directly owns 9,721 shares of the company’s stock, valued at $4,926,213.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,058 shares of company stock valued at $17,588,116. 0.35% of the stock is currently owned by company insiders. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Bradley Foster & Sargent Inc. CT Boosts Stock Position in Canadian Pacific Kansas City Limited (NYSE:CP) Bradley Foster & Sargent Inc. CT Buys New Position in Casey’s General Stores, Inc. (NASDAQ:CASY)
--------------------------------------------------

Title: Elevance Health, Inc. (NYSE:ELV) Sees Large Increase in Short Interest
URL: https://www.etfdailynews.com/2024/09/19/elevance-health-inc-nyseelv-sees-large-increase-in-short-interest/
Time Published: 2024-09-19T16:58:25Z
Full Content:
Posted by MarketBeat News on Sep 19th, 2024 Elevance Health, Inc. (NYSE:ELV – Get Free Report) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,780,000 shares, a growth of 6.6% from the August 15th total of 1,670,000 shares. Based on an average daily trading volume, of 962,600 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.8% of the company’s shares are sold short. ELV stock traded up $1.22 during trading on Thursday, hitting $540.68. 56,008 shares of the stock traded hands, compared to its average volume of 1,001,137. Elevance Health has a 1 year low of $431.38 and a 1 year high of $567.26. The firm’s 50 day moving average is $536.03 and its two-hundred day moving average is $528.77. The stock has a market cap of $125.66 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 1.19 and a beta of 0.82. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.49. Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 EPS for the quarter, beating the consensus estimate of $9.99 by $0.13. The company had revenue of $43.22 billion for the quarter, compared to the consensus estimate of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. Elevance Health’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the prior year, the firm posted $9.04 EPS. On average, sell-side analysts anticipate that Elevance Health will post 37.25 EPS for the current year. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be issued a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Tuesday, September 10th. Elevance Health’s payout ratio is presently 24.64%. In related news, Director Robert L. Dixon, Jr. sold 305 shares of the company’s stock in a transaction on Friday, July 19th. The shares were sold at an average price of $506.76, for a total transaction of $154,561.80. Following the completion of the sale, the director now directly owns 9,721 shares in the company, valued at approximately $4,926,213.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the company’s stock in a transaction on Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the transaction, the director now directly owns 9,721 shares in the company, valued at approximately $4,926,213.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the transaction, the director now owns 8,744 shares of the company’s stock, valued at $4,647,610.88. The disclosure for this sale can be found here. Insiders sold 35,058 shares of company stock worth $17,588,116 in the last three months. 0.35% of the stock is owned by insiders. Institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Elevance Health by 114.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 31,311 shares of the company’s stock valued at $14,765,000 after acquiring an additional 16,737 shares during the last quarter. Brave Warrior Advisors LLC boosted its holdings in shares of Elevance Health by 7.9% during the 4th quarter. Brave Warrior Advisors LLC now owns 1,756,653 shares of the company’s stock valued at $828,367,000 after acquiring an additional 129,055 shares during the last quarter. New Mexico Educational Retirement Board boosted its holdings in shares of Elevance Health by 14.6% during the 1st quarter. New Mexico Educational Retirement Board now owns 14,146 shares of the company’s stock valued at $6,949,000 after acquiring an additional 1,800 shares during the last quarter. Bank of Nova Scotia boosted its holdings in shares of Elevance Health by 276.0% in the fourth quarter. Bank of Nova Scotia now owns 82,331 shares of the company’s stock worth $38,823,000 after buying an additional 60,436 shares during the last quarter. Finally, Blair William & Co. IL boosted its holdings in shares of Elevance Health by 119.7% in the first quarter. Blair William & Co. IL now owns 12,134 shares of the company’s stock worth $6,292,000 after buying an additional 6,610 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock. Several research analysts have commented on ELV shares. StockNews.com lowered shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 6th. Stephens reiterated an “overweight” rating and issued a $615.00 price target on shares of Elevance Health in a research note on Thursday, September 5th. Robert W. Baird initiated coverage on shares of Elevance Health in a research note on Thursday, May 30th. They issued an “outperform” rating and a $649.00 price target for the company. Wells Fargo & Company decreased their price target on shares of Elevance Health from $600.00 to $593.00 and set an “overweight” rating for the company in a research note on Monday, July 22nd. Finally, Morgan Stanley initiated coverage on shares of Elevance Health in a research note on Monday, June 24th. They issued an “overweight” rating and a $643.00 price target for the company. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Elevance Health presently has an average rating of “Buy” and a consensus target price of $604.29. Read Our Latest Stock Report on Elevance Health (Get Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Macquarie Lowers Walt Disney (NYSE:DIS) Price Target to $91.00 KLA Co. (NASDAQ:KLAC) Shares Sold by Leuthold Group LLC
--------------------------------------------------

Title: Elevance Health, Inc. (NYSE:ELV) Sees Large Growth in Short Interest
URL: https://www.etfdailynews.com/2024/09/19/elevance-health-inc-nyseelv-sees-large-growth-in-short-interest/
Time Published: 2024-09-19T16:12:49Z
Full Content:
Posted by MarketBeat News on Sep 19th, 2024 Elevance Health, Inc. (NYSE:ELV – Get Free Report) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 1,780,000 shares, an increase of 6.6% from the August 15th total of 1,670,000 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average trading volume of 962,600 shares, the short-interest ratio is presently 1.8 days. Several research firms have commented on ELV. Cantor Fitzgerald reissued an “overweight” rating and set a $600.00 target price on shares of Elevance Health in a research note on Tuesday, September 10th. Bank of America reiterated a “neutral” rating and set a $530.00 price objective (down previously from $646.00) on shares of Elevance Health in a research note on Thursday, July 18th. Baird R W upgraded Elevance Health to a “strong-buy” rating in a research report on Thursday, May 30th. Morgan Stanley started coverage on Elevance Health in a research report on Monday, June 24th. They set an “overweight” rating and a $643.00 price target on the stock. Finally, TD Cowen cut their price objective on Elevance Health from $624.00 to $589.00 and set a “buy” rating for the company in a report on Friday, July 19th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Elevance Health has an average rating of “Buy” and an average target price of $604.29. Read Our Latest Stock Analysis on Elevance Health Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever ELV stock traded up $2.04 during mid-day trading on Thursday, reaching $541.50. 23,080 shares of the stock traded hands, compared to its average volume of 1,000,955. Elevance Health has a 52-week low of $431.38 and a 52-week high of $567.26. The stock’s fifty day moving average is $536.03 and its 200-day moving average is $528.77. The company has a market cap of $125.85 billion, a P/E ratio of 20.39, a P/E/G ratio of 1.19 and a beta of 0.82. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.99 by $0.13. Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. The business had revenue of $43.22 billion during the quarter, compared to analyst estimates of $42.99 billion. During the same period in the previous year, the company earned $9.04 EPS. The firm’s revenue was down .4% on a year-over-year basis. As a group, sell-side analysts expect that Elevance Health will post 37.25 earnings per share for the current year. The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th will be given a $1.63 dividend. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 annualized dividend and a yield of 1.20%. Elevance Health’s dividend payout ratio is 24.64%. In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction on Friday, July 19th. The shares were sold at an average price of $506.76, for a total transaction of $154,561.80. Following the sale, the director now directly owns 9,721 shares of the company’s stock, valued at $4,926,213.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Robert L. Dixon, Jr. sold 305 shares of Elevance Health stock in a transaction dated Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the sale, the director now directly owns 9,721 shares in the company, valued at approximately $4,926,213.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Gail Boudreaux sold 34,000 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total value of $17,033,320.00. Following the transaction, the chief executive officer now owns 126,709 shares of the company’s stock, valued at $63,478,674.82. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,058 shares of company stock valued at $17,588,116. Corporate insiders own 0.35% of the company’s stock. A number of hedge funds and other institutional investors have recently made changes to their positions in ELV. Massachusetts Financial Services Co. MA increased its stake in shares of Elevance Health by 34.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,062,706 shares of the company’s stock valued at $1,117,698,000 after buying an additional 523,910 shares during the period. Morningstar Investment Services LLC bought a new position in Elevance Health in the fourth quarter valued at approximately $239,244,000. Focused Investors Fund L P bought a new position in shares of Elevance Health in the 1st quarter valued at about $249,884,000. M&G Plc acquired a new position in shares of Elevance Health during the 1st quarter worth approximately $203,389,000. Finally, Maj Invest Holding A S bought a new position in Elevance Health in the 2nd quarter valued at about $173,753,000. 89.24% of the stock is owned by institutional investors. (Get Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Wealth Alliance Decreases Position in Manulife Financial Co. (NYSE:MFC) Burgundy Asset Management Ltd. Sells 228,117 Shares of EMCOR Group, Inc. (NYSE:EME)
--------------------------------------------------

Title: Moors & Cabot Inc. Trims Stake in Elevance Health, Inc. (NYSE:ELV)
URL: https://www.etfdailynews.com/2024/09/19/moors-cabot-inc-trims-stake-in-elevance-health-inc-nyseelv/
Time Published: 2024-09-19T14:19:06Z
Full Content:
Posted by MarketBeat News on Sep 19th, 2024 Moors & Cabot Inc. reduced its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 8.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,007 shares of the company’s stock after selling 180 shares during the period. Moors & Cabot Inc.’s holdings in Elevance Health were worth $1,088,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Richwood Investment Advisors LLC increased its holdings in Elevance Health by 0.8% during the fourth quarter. Richwood Investment Advisors LLC now owns 2,546 shares of the company’s stock valued at $1,201,000 after buying an additional 20 shares during the last quarter. Bell Investment Advisors Inc increased its stake in shares of Elevance Health by 2.1% in the fourth quarter. Bell Investment Advisors Inc now owns 989 shares of the company’s stock worth $466,000 after purchasing an additional 20 shares in the last quarter. Capital Advisors Ltd. LLC increased its stake in shares of Elevance Health by 8.8% in the first quarter. Capital Advisors Ltd. LLC now owns 248 shares of the company’s stock worth $129,000 after purchasing an additional 20 shares in the last quarter. Bedel Financial Consulting Inc. increased its stake in shares of Elevance Health by 1.6% in the first quarter. Bedel Financial Consulting Inc. now owns 1,247 shares of the company’s stock worth $647,000 after purchasing an additional 20 shares in the last quarter. Finally, American Trust increased its stake in shares of Elevance Health by 2.6% in the first quarter. American Trust now owns 775 shares of the company’s stock worth $402,000 after purchasing an additional 20 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors. In related news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the transaction, the director now directly owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the transaction, the director now directly owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Gail Boudreaux sold 34,000 shares of Elevance Health stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the transaction, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at $63,478,674.82. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,058 shares of company stock valued at $17,588,116. Company insiders own 0.35% of the company’s stock. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever A number of brokerages have recently issued reports on ELV. Royal Bank of Canada increased their price objective on shares of Elevance Health from $575.00 to $585.00 and gave the stock an “outperform” rating in a research note on Thursday, July 18th. Robert W. Baird initiated coverage on shares of Elevance Health in a research note on Thursday, May 30th. They issued an “outperform” rating and a $649.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $600.00 target price on shares of Elevance Health in a research report on Tuesday, September 10th. Baird R W upgraded shares of Elevance Health to a “strong-buy” rating in a research report on Thursday, May 30th. Finally, Barclays dropped their target price on shares of Elevance Health from $621.00 to $611.00 and set an “overweight” rating for the company in a research report on Thursday, July 18th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Elevance Health currently has an average rating of “Buy” and a consensus target price of $604.29. Check Out Our Latest Report on ELV Shares of NYSE:ELV opened at $539.46 on Thursday. Elevance Health, Inc. has a 52 week low of $431.38 and a 52 week high of $567.26. The stock has a market capitalization of $125.38 billion, a P/E ratio of 20.39, a PEG ratio of 1.19 and a beta of 0.82. The firm has a fifty day simple moving average of $536.03 and a two-hundred day simple moving average of $528.77. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 EPS for the quarter, topping analysts’ consensus estimates of $9.99 by $0.13. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The business had revenue of $43.22 billion during the quarter, compared to analysts’ expectations of $42.99 billion. During the same period last year, the company posted $9.04 EPS. The business’s revenue was down .4% on a year-over-year basis. On average, analysts expect that Elevance Health, Inc. will post 37.25 earnings per share for the current fiscal year. The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th will be paid a dividend of $1.63 per share. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.21%. Elevance Health’s dividend payout ratio is presently 24.64%. (Free Report) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Edgestream Partners L.P. Buys New Shares in Griffon Co. (NYSE:GFF) Wealth Alliance Trims Holdings in BlackRock, Inc. (NYSE:BLK)
--------------------------------------------------

Title: Brokerages Set Elevance Health, Inc. (NYSE:ELV) Price Target at $604.29
URL: https://www.etfdailynews.com/2024/09/19/brokerages-set-elevance-health-inc-nyseelv-price-target-at-604-29-2/
Time Published: 2024-09-19T07:22:44Z
Full Content:
Posted by MarketBeat News on Sep 19th, 2024 Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been assigned a consensus recommendation of “Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $604.29. A number of equities analysts recently weighed in on ELV shares. JPMorgan Chase & Co. boosted their price target on shares of Elevance Health from $628.00 to $631.00 and gave the stock an “overweight” rating in a research report on Thursday, May 30th. Truist Financial upped their price target on Elevance Health from $600.00 to $620.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Wells Fargo & Company reduced their price objective on Elevance Health from $600.00 to $593.00 and set an “overweight” rating on the stock in a research report on Monday, July 22nd. Baird R W upgraded Elevance Health to a “strong-buy” rating in a report on Thursday, May 30th. Finally, TD Cowen reduced their price target on Elevance Health from $624.00 to $589.00 and set a “buy” rating on the stock in a report on Friday, July 19th. Check Out Our Latest Stock Report on ELV Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Shares of ELV opened at $539.46 on Monday. The firm has a market cap of $125.38 billion, a P/E ratio of 20.39, a PEG ratio of 1.19 and a beta of 0.82. Elevance Health has a 12 month low of $431.38 and a 12 month high of $567.26. The stock’s 50 day moving average is $536.03 and its two-hundred day moving average is $528.77. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.99 by $0.13. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The business had revenue of $43.22 billion for the quarter, compared to the consensus estimate of $42.99 billion. During the same period last year, the firm posted $9.04 earnings per share. The company’s revenue was down .4% compared to the same quarter last year. Analysts predict that Elevance Health will post 37.25 earnings per share for the current fiscal year. The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th will be paid a dividend of $1.63 per share. The ex-dividend date is Tuesday, September 10th. This represents a $6.52 annualized dividend and a yield of 1.21%. Elevance Health’s payout ratio is 24.64%. In other Elevance Health news, CEO Gail Boudreaux sold 34,000 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the completion of the transaction, the chief executive officer now owns 126,709 shares in the company, valued at approximately $63,478,674.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Gail Boudreaux sold 34,000 shares of the company’s stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the completion of the transaction, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at approximately $63,478,674.82. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ramiro G. Peru sold 753 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total value of $400,234.56. Following the completion of the transaction, the director now owns 8,744 shares in the company, valued at approximately $4,647,610.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,058 shares of company stock worth $17,588,116. 0.35% of the stock is currently owned by company insiders. Several hedge funds have recently made changes to their positions in ELV. Accretive Wealth Partners LLC purchased a new position in shares of Elevance Health during the fourth quarter worth approximately $209,000. ING Groep NV purchased a new stake in shares of Elevance Health in the fourth quarter valued at about $1,119,000. PNC Financial Services Group Inc. raised its holdings in shares of Elevance Health by 1.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 81,298 shares of the company’s stock valued at $38,337,000 after buying an additional 1,226 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its stake in shares of Elevance Health by 3.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 1,172 shares of the company’s stock worth $553,000 after buying an additional 42 shares during the period. Finally, Coldstream Capital Management Inc. grew its holdings in shares of Elevance Health by 0.7% during the fourth quarter. Coldstream Capital Management Inc. now owns 3,471 shares of the company’s stock worth $1,637,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock. (Get Free Report Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter. Whirlpool Co. (NYSE:WHR) Receives $103.75 Average PT from Brokerages Essex Property Trust, Inc. (NYSE:ESS) Receives $288.30 Consensus PT from Analysts
--------------------------------------------------